Niche Pharmaceutical Valuation Software Business with Low Down Payment and Royalty Structure

This listing presents a niche software business specializing in pharmaceutical valuation. The company's flagship product offers advanced tools for project evaluation and portfolio analysis, designed to be more flexible and user-friendly than traditional methods like Excel. Key features include real-time decision-making capabilities, financial projection generation, and optimization through sophisticated modeling techniques such as Monte Carlo simulations and tornado charts. The software is highly customizable and can integrate diverse project types, making it attractive to pharmaceutical companies and consulting firms.

Historically, revenue has been generated primarily through consulting services and licensing fees, with clients paying up to $50,000 annually. While direct software sales are currently underutilized, there is significant potential for scaling this model, especially as the source code is included in the sale. The current owner is available for paid programming and development support to ensure the software's continued evolution.

The business is offered with a low upfront investment of $25,000, complemented by a 20% royalty on future sales, presenting a low-risk entry point for buyers. The seller will retain usage rights exclusively for consulting, allowing the buyer full freedom to expand software sales. A smooth transition is assured with exceptional support and training from the seller, and the experienced staff are willing to remain with the new owner, ensuring operational continuity. The business was founded in 2020 and is located in Nevada. The reason for sale is retirement.